Satellos Bioscience (MSLE) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Stablecoin Development (SDEV) over the past year, gaining 5.4% versus a loss of 55.9%. Over five years, MSLE leads with a -48.9% price change compared with -99.9% for SDEV. Satellos Bioscience is the larger company by market cap ($161.9 million vs $143.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | SDEV |
|---|---|---|
| Share price | $7.63 | $2.78 |
| Market cap | $161.88M | $143.87M |
| 1-day change | +1.19% | -14.46% |
| YTD return | +29.76% | -90.14% |
| 1-year return | +5.44% | -55.87% |
| 5-year return | -48.93% | -99.92% |
| EPS (TTM) | $-1.95 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.40 | $99.75 |
| 52-week low | $5.30 | $0.78 |
| Distance from 52-week high | -43.04% | -97.21% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +244.04% | — |
| Average volume | 51.29K | 11.42M |
| Shares outstanding | 21.22M | 51.75M |
| Employees | 18 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed SDEV by 61.3 percentage points over the past year.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
MSLE vs SDEV FAQ
Which is bigger, Satellos Bioscience or Stablecoin Development?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $161.88M compared with $143.87M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, MSLE or SDEV?
MSLE returned +5.44% over the past 12 months, compared with -55.87% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.